| 0.7525 0.022 (2.94%) | 03-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.91 | 1-year : | 1.02 |
| Resists | First : | 0.78 | Second : | 0.87 |
| Pivot price | 0.79 |
|||
| Supports | First : | 0.64 | Second : | 0.53 |
| MAs | MA(5) : | 0.78 |
MA(20) : | 0.78 |
| MA(100) : | 1.25 |
MA(250) : | 1.74 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 19.7 |
D(3) : | 35.6 |
| RSI | RSI(14): 39.6 |
|||
| 52-week | High : | 3.17 | Low : | 0.64 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MXCT ] has closed above bottom band by 17.7%. Bollinger Bands are 63.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.79 - 0.79 | 0.79 - 0.8 |
| Low: | 0.72 - 0.73 | 0.73 - 0.73 |
| Close: | 0.74 - 0.75 | 0.75 - 0.76 |
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
Thu, 19 Mar 2026
MaxCyte (MXCT) CFO covers RSU tax withholding through automatic share sale - Stock Titan
Thu, 19 Mar 2026
MaxCyte, Inc. $MXCT Shares Bought by Mirabella Financial Services LLP - MarketBeat
Wed, 18 Mar 2026
MaxCyte (MXCT) launches ExPERT DTx platform to accelerate high-throughput drug discovery - MSN
Tue, 17 Mar 2026
Mirabella Financial Services LLP Purchases 1,600,000 Shares of MaxCyte, Inc. $MXCT - MarketBeat
Tue, 17 Mar 2026
MaxCyte (MXCT) Projected to Post Earnings on Tuesday - MarketBeat
Tue, 24 Feb 2026
New MaxCyte lab device runs 96 cell samples in a three-minute cycle - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 107 (M) |
| Shares Float | 105 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 75.9 (%) |
| Shares Short | 5,090 (K) |
| Shares Short P.Month | 2,500 (K) |
| EPS | -0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.69 |
| Profit Margin | -132.6 % |
| Operating Margin | -162.5 % |
| Return on Assets (ttm) | -13.7 % |
| Return on Equity (ttm) | -23.2 % |
| Qtrly Rev. Growth | -16.4 % |
| Gross Profit (p.s.) | 0.25 |
| Sales Per Share | 0.32 |
| EBITDA (p.s.) | -0.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -40 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -1.75 |
| PEG Ratio | 0 |
| Price to Book value | 0.44 |
| Price to Sales | 2.33 |
| Price to Cash Flow | -2.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|